UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(D) OF THE 

SECURITIES EXCHANGE ACT OF 1934 

Date of Report (Date of earliest event reported): January 7, 2019 

CELGENE CORPORATION 

(Exact name of registrant as specified in its charter) 

 [DATA_TABLE_REMOVED]  

  86 Morris Avenue, Summit, New Jersey       07901   

  (Address of principal executive offices)       (Zip Code)     

Registrant’s telephone number, including area code: (908) 673-9000 

(Former name or former address, if changed since last report.) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company o 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION 

On January 7, 2019, Celgene Corporation (the “Company”) provided a business update and financial guidance for 2019 at the 37th Annual J.P. Morgan Healthcare Conference. The business update and financial guidance is included in the attached press release, which is incorporated herein by reference. The Company expects to report its 2018 fourth-quarter and full-year financial results on Thursday, January 31, 2019. 

The information in this Current Report on Form 8-K, including the exhibit attached hereto, is furnished solely pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information in this Current Report on Form 8-K, including the exhibit attached hereto, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended. 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS 

Exhibit 99.1 — Press Release dated January 7, 2019 

This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be “filed.” 

EXHIBIT INDEX 

  Exhibit No.       Description   

  99.1       Press Release dated January 7, 2019    

2 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

3